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Summary Background Axitinib is an oral, potent and
selective inhibitor of vascular endothelial growth factor
receptors (VEGFRs) 1, 2 and 3. We report on data obtained
from 18 Japanese patients with advanced solid tumors in
two phase I trials that evaluated the safety, pharmacokinet-
ics and antitumor activity of axitinib and also examined
potential biomarkers. Methods Six patients received a
single 5-mg dose of axitinib followed by 5 mg twice daily
(BID), and an additional six patients received axitinib 5 mg
BID only. Another six patients received axitinib at 5-mg,
7-mg and 10-mg single doses followed by 5 mg BID.
Results Plasma pharmacokinetics following single doses of
axitinib was generally linear. Common treatment-related
adverse events were fatigue (83%), anorexia (72%),
diarrhea (67%), hand–foot syndrome (67%) and hyperten-
sion (61%). Sixteen patients (89%) experienced thyroid-
stimulating hormone (TSH) elevation. Grade 3/4 toxicities
included hypertension (33%) and fatigue (28%). No grade
3/4 fatigue occurred in patients who started thyroid
hormone replacement therapy when TSH was elevated.
Thyroglobulin elevation was observed in all patients who
continued treatment with axitinib for ≥3 months. Abnormal
TSH correlated with exposure to axitinib (r=0.72).
Decrease in soluble (s) VEGFR-2 levels significantly
correlated with exposure to axitinib (r=–0.94). Axitinib
showed antitumor activity across multiple tumor types.
Conclusions Axitinib-related thyroid dysfunction could be
due to a direct effect on the thyroid gland. Grade 3/4 fatigue
and hypothyroidism appear to be controllable with use of
thyroid hormone replacement therapy. sVEGFR-2 and TSH
may act as biomarkers of axitinib plasma exposure.
Keywords Axitinib.Fatigue.Thyroid dysfunction.
Biomarker.Pharmacokinetics.Vascular endothelial growth
factor receptor
Introduction
Axitinib (AG-013736) is an oral, potent and selective inhibitor
of vascular endothelial growth factor (VEGF) receptors
(VEGFRs) 1, 2 and 3. Inhibition of the associated receptor
tyrosine kinases is seen at picomolar concentrations [1].
Inhibition of the VEGF/VEGFR pathway by axitinib reduces
VEGF-stimulated receptor autophosphorylation, blocking the
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DOI 10.1007/s10637-011-9637-1growth and survival of endothelial cells, reducing tumor
vascularization and inducing cell death [2]. Antitumor effects
have been documented in a range of preclinical models, using
single-agent axitinib or in combination with chemotherapy
[3, 4]. Clinical activity with axitinib monotherapy, at a
recommended starting dose of 5 mg twice daily (BID), has
been observed in phase II studies in patients with metastatic
renal cell carcinoma (mRCC) refractory to treatment with
cytokines [5]o rs o r a f e n i b[ 6]. Two multicenter phase III
studies of axitinib in advanced RCC are ongoing. Antitumor
activity also has been noted in trials of axitinib in patients with
advanced non-small cell lung cancer (NSCLC) [7], thyroid
cancer [8], melanoma [9] and breast cancer [10].
A phase I study (Study 1) was conducted in 12 Japanese
patients with solid tumors to determine the recommended
starting dose for this patient population. This study also
investigated the safety, pharmacokinetics following axitinib
5-mg single dosing and continuous dosing, the antitumor
activity and potential biomarkers associated with single-
agent axitinib [11]. Subsequently, a second phase I study
(Study 2) was conducted in an additional six Japanese
patients with solid tumors to evaluate pharmacokinetics
following axitinib 5-mg, 7-mg, 10-mg single dosing and
continuous dosing. In Study 1, fatigue and abnormal thyroid-
stimulating hormone (TSH) levels were frequently observed
in 12 patients. In Study 2, therefore, free T3, free T4 and
thyroglobulinwereprospectivelymeasuredtofurtherevaluate
the effects of axitinib on the thyroid. Study 2 also explored
biomarkers and antitumor activity. In this report, we newly
reported the axitinib pharmacokinetic profile following 5-mg,
7-mg and 10-mg single dosing, thyroid function tests for free
T3, free T4 and thyroglobulin, and management of fatigue
with thyroid hormone replacement therapy. In addition, we
updated safety data, antitumor activity, and the relationship
between TSH level or soluble (s) VEGFR-2 versus axitinib
exposure in 18 patients compared with the 12 patients
evaluated in the initial phase I study (Study 1) [11].
The objectives of this analysis were to (1) evaluate the safety
of axitinib in Japanese patients, including effects on fatigue and
thyroid function; (2) evaluate plasma pharmacokinetics follow-
ing axitinib 5-mg, 7-mg and 10-mg single and continuous
dosing; (3) investigate plasma levels of VEGF, sVEGFR-2,
sVEGFR-3 and soluble stem cell factor receptor (sKIT) and
their potential as biomarkers; and (4) assess the preliminary
antitumor activity of axitinib in this patient population.
Methods
Patient population
Patients were eligible for these studies if they had histolog-
ically or cytologically diagnosed advanced malignant solid
tumorsandwereeitherineligiblefor,orrefractoryto, standard
therapies;aged20–75yearsinStudy1 and≥20years inStudy
2; expected survival ≥3 months; adequate bone marrow, renal
and hepatic function; Eastern Cooperative Oncology Group
performance status (ECOG PS) 0, 1 or 2; and no proteinuria
(dipstick value <1+ or <500 mg per 24-h urine collection
if ≥1+ in Study 1 and <1+ or <2 g per 24-h urine collection
if ≥1+ in Study 2).
Patients with uncontrolled hypertension at screening
(defined as blood pressure [BP] >130/80 mm Hg in Study
1 and >140/90 mm Hg in Study 2) were excluded, although
use of antihypertensive agents was permitted. No anticancer
therapy in the previous 4 weeks was allowed and no
hormonal therapy, radiotherapy, oral fluorinated pyrimidine
drugoramolecularlytargetedagentwaspermittedfor≥2weeks
prior to initiation of axitinib.
Other key exclusion criteria included the presence of
central lung lesions involving major blood vessels; active
gastrointestinal (GI) bleeding or GI disorders that could affect
axitinib ingestion or absorption; active seizure disorder or
brain metastases with symptoms or requiring treatment;
cardiovascular disease in the previous 12 months, including
myocardial infarction, severe or unstable angina, coronary
artery/peripheral artery bypass graft or symptomatic conges-
tive heart failure; cerebrovascular disorders, such as transient
cerebral ischemic attack, deep vein thrombosis or pulmonary
embolus, in the previous 12 months; and grade ≥3h e m o r -
rhage within 4 weeks or hemoptysis (>2.5 mL bright-red
blood per day) within the week prior to enrollment. Patients
were also excluded if they were receiving or likely to receive
drugsorfoodthatcouldactaspotentcytochromeP450(CYP)
3A4 inhibitors or CYP3A4 or CYP1A2 inducers, as were
patients requiring anticoagulant therapy.
Study protocols were approved by the Institutional
Review Board of the National Cancer Center, Tokyo, Japan
(Study 1) and Kobe University Hospital, Kobe, Japan
(Study 2). All patients provided written informed consent.
The studies were conducted in accordance with the Declara-
tion of Helsinki and the International Conference on
Harmonization guidelines on Good Clinical Practice, as well
as all applicable local regulatory requirements and laws.
The trials reported here are registered on the clinical trials
site of the US National Cancer Institute website (Study 1, http://
www.clinicaltrials.gov/ct/show/NCT00447005; Study 2,
http://www.clinicaltrials.gov/ct/show/NCT00726752).
Drug administration
In Study 1 (N=12), the first six patients received a single
5-mg dose of axitinib. If well tolerated over the initial 48 h,
they received continuous axitinib 5 mg BID for the first
28-day cycle (Fig. 1). Axitinib single 5-mg dosing was
administered to the first 6 patients only in order to evaluate
1056 Invest New Drugs (2012) 30:1055–1064axitinib terminal-phase plasma half-life. The observation
period (48 h) was set to evaluate the pharmacokinetics of
axitinib up to 32 h after axitinib single 5-mg dosing. This
observation period was also used in the first-in-human (FIH)
study previously conducted in Caucasian patients. The same
observation period was used to maintain consistency between
both phase I studies conducted in Western and Japan. If
axitinib was well tolerated with no treatment-related grade >2
adverse events occurring over a consecutive 2-week period in
subsequent cycles, the dose of axitinib could be increased to
7m gB I Da n dt h e nt oam a x i m u m1 0m gB I Dc o n t i n u o u s
dosing unless systolic BP (sBP) was >150 mm Hg, diastolic
BP (dBP) >90 mm Hg and the patient was receiving
antihypertension medication. The axitinib dose could be
r e d u c e dt o3m gB I Da n dt h e nt o2m gB I Di nt h ee v e n to f
treatment-related toxicity or patient intolerance. An additional
six patients in this study were started on continuous axitinib
dosing at 5 mg BID without receiving an initial single dose.
In Study 2 (N=6), patients received a single dose of
5 mg axitinib followed by a single dose of 7 mg and then
10 mg (Fig. 1). If these doses were safely administered,
patients could receive continuous axitinib 5-mg BID dosing
for the first 14 days. Subsequently, these patients also had
the option of dose titration (increase or decrease) during the
continuous dosing period.
In both studies, axitinib was administered orally in a fed
state. A food effect study conducted in Western healthy
volunteers demonstrated that lower plasma exposure of
axitinib was obtained in the fed state versus overnight
fasting state [12]. However, there was no difference in
exposure of axitinib between the fed state and shorter
fasting durations (i.e. 2 h before and 2 h after dosing, and
1 h before and 1 h after dosing, respectively). Since it was
considered impractical for patients to be “overnight fasted”
around each of the two daily doses of axitinib, and in order
to avoid fluctuations in plasma exposures between morning
and evening doses of the drug, axitinib administration in the
fed state was recommended.
The axitinib dose was reduced or interrupted in both trials
ifdrug-relatedtoxicityoccurredaccordingtopredefineddose-
modificationcriteria.Axitinibtreatmentwasinterruptedorthe
dose was reduced if patients developed hemoptysis, hyper-
tension (sBP >150 mm Hg or dBP >100 mm Hg) despite
institution of maximal antihypertensive therapy or proteinuria
(≥2 g/24 h). Patients continued axitinib therapy until disease
progression, intolerable toxicity or withdrawal of consent.
Study assessments
Safety
Adverse events were assessed throughout the studies using
Common Toxicity Criteria for Adverse Events, version 3.0.
In Study 1, TSH measurements were performed every week
in cycle 1, then every 2 weeks. In Study 2, antithyroper-
oxidase (anti-TPO) and antithyroglobulin antibody titers
were determined at screening; TSH, free triiodothyronine
(free T3), free thyroxine (free T4) and thyroglobulin were
measured every week in cycle 1 and every 2 weeks
thereafter. In addition, total cholesterol and creatine
phosphokinase (CPK), which were potentially relevant to
thyroid function, were also measured. Previous studies have
found evidence of hypothyroidism in patients treated with
other antiangiogenic agents, such as sunitinib, and related
symptoms (including fatigue) improved with administration
of thyroid hormone replacement therapy [6, 13]. In Study 2,
thyroid function–test values were prospectively monitored
at every visit, and thyroid hormone replacement therapy
was proactively given to patients, as appropriate according
to TSH levels, to maintain a euthyroid state.
Pharmacokinetics
To assess axitinib pharmacokinetics, blood samples were
collected from patients who received 5-mg, 7-mg and 10-mg
single doses (pre-dose and 0.5, 1, 2, 4, 6, 8, 10, 24 and 32 h
Study 1
Study 2
Days
Cycle 1 Subsequent cycles
1 28 56
5 mg BID
5 mg BID
(option to titrate a)
N=12 (including initial 6 patients) N=6 
5 mg
–1
Cycle 1
1 14 28 56
5 mg BID
Subsequent cycles
7 mg
10 mg
5 mg
N=6 b
–1 –3 –5 Days
5 mg BID
(option to titrate a)
5 mg BID
(option to titrate a)
Fig. 1 Study schemas. BID,
twice daily.
a 5 mg BID could be
titrated up to 7 mg BID, then
10 mg BID or interrupted/
reduced to 3 mg BID, then 2 mg
BID.
b All patients in Study 2
received axitinib at 5-mg, 7-mg
and 10-mg single doses on
days –5, –3 and –1
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duringcontinuousdosing(pre-doseand0.5,1,2,4,8and12h
postdose)atcycle1day1andcycle1day15inStudy1andat
cycle 1 day 15 in Study 2. Pharmacokinetic parameters
evaluated for single doses included maximum plasma
concentration (Cmax), area under the plasma concentration–
time curve (AUC) from time zero to infinity (AUCinf), time
to first occurrence of Cmax (Tmax) and terminal-phase plasma
half-life (t1/2). AUC over the dosing interval (AUC from
time zero to 12 h [AUC12]) and accumulation ratio (Rac)
were also measured following continuous dosing.
Blood samples were centrifuged at 1,000 ×g for 15 min
and plasma was stored frozen at –20°C. Plasma samples
were analyzed for axitinib concentration at Charles River
Laboratories, Inc. (Worcester, MA, USA) using a validated
high-performance liquid chromatography–tandem mass
spectrometric method; the lower limit of quantification
was 0.1 ng/mL.
Soluble biomarkers
Plasma samples were collected to assess changes in soluble
protein biomarkers that might be associated with axitinib-
induced VEGF/VEGFR inhibition. Plasma concentrations
of VEGF, sVEGFR-2, sVEGFR-3 and sKIT were measured
in patient blood samples at baseline and during treatment
on day 1 of each cycle up to 12 cycles and at the end of
treatment. Each biomarker was measured using an enzyme-
linked immunosorbent assay (ELISA) kit at Alta Analysis
(San Diego, CA, USA). Exploratory analyses were con-
ducted to investigate the relationship between these
endpoints and pharmacokinetics.
Preliminary antitumor activity
Antitumor activity was assessed at screening, every
8 weeks during continuous dosing and at the end of study,
according to Response Evaluation Criteria in Solid Tumors
(RECIST, version 1.0) [14].
Results
Patient demographics
Patient demographics and baseline characteristics for the
two studies are shown in Table 1. Of the 18 patients
enrolled in the two studies, the majority had an ECOG PS
of 0 or 1. The most common tumor type was colorectal
cancer. Most patients were heavily pretreated; 14/18
patients (78%) had received ≥3 prior systemic treatment
regimens. Six patients were receiving concurrent antihy-
pertension medication at the start of axitinib therapy.
Safety
Common treatment-related adverse events are shown in
Table 2 and treatment-related laboratory abnormalities for
the two studies are listed in Table 3. The most common
adverse events (all grades) were fatigue, anorexia, diarrhea,
hand–foot syndrome and hypertension. Grade 3/4 adverse
events were infrequent and mainly limited to fatigue and
hypertension. The most frequent treatment-related labora-
tory abnormality was increased TSH, but all cases were
low-grade in severity. Proteinuria occurred in nine patients,
with grade 3/4 proteinuria seen in two patients.
Pharmacokinetics
Plasma pharmacokinetic parameters following single and
continuous dosing of axitinib in Study 2 (N=6) are shown
in Table 4. The plasma pharmacokinetics following single
dosing of 5 mg, 7 mg and 10 mg axitinib seemed to be
generally linear. The plasma axitinib concentration profiles
Table 1 Patient demographics and baseline characteristics (pooled
data from Study 1 and Study 2)
N=18
Median age (range), y 63 (25–75)
Gender, n (%)
Male 10 (56)
Female 8 (44)
ECOG PS, n (%)
0 7 (39)
1 10 (56)
2 1 (6)
Tumor type, n (%)
Colorectal cancer 6 (33)
Renal cell cancer 2 (11)
Liposarcoma 2 (11)
Other
a 8 (44)
No. of prior systemic treatment regimens, n (%)
1 3 (17)
2 1 (6)
3 5 (28)
4 4 (22)
≥5 5 (28)
Concurrent antihypertensive agent, n (%)
Yes 6 (33)
No 12 (67)
aOvarian cancer; non-small cell lung cancer; thymic cancer; synovial
sarcoma; esophageal malignant melanoma; hypopharynx cancer; gastric
cancer; pancreatic cancer
ECOG PS Eastern Cooperative Oncology Group performance status
1058 Invest New Drugs (2012) 30:1055–1064after single-dose administration are shown in Fig. 2.
Following a single dose of axitinib, the plasma concentra-
tion reached a maximum (Cmax) at ~4 h after administration
and was eliminated with a half-life of 4.8–5.9 h. The mean
(% coefficient of variation) Rac after continuous dosing was
1.37 (28%), consistent with the value predicted from the
mean half-life of axitinib.
Thyroid function
In the two studies, 16 patients (89%) experienced elevation
of TSH above the upper limit of normal range. Changes in
TSH, free T3, free T4 and thyroglobulin levels over time
for patients in Study 2 are shown in Fig. 3a–e. While the
kinetics of response varied, all three patients who continued
treatment with axitinib for ≥3 months exhibited an increase
in thyroglobulin levels between day 100 and day 200
following initiation of axitinib therapy, which subsequently
returned to baseline (Fig. 3e). Normalization of thyroglob-
ulin levels was associated with the elevation of TSH levels
in these patients. One of six patients had positive
antithyroglobulin antibody titers at baseline and another
one patient tested positive for anti-TPO antibody in Study
2. Changes in thyroid function tests were observed in
patients regardless of baseline antithyroglobulin/anti-TPO
antibody status.
Thyroid hormone replacement therapy was proactively
given to patients enrolled in Study 2, according to TSH
levels measured at each visit, to maintain a euthyroid state.
As shown in Table 5, while grade 3/4 fatigue occurred in
42% of patients in Study 1, no cases of grade 3/4 fatigue
were noted in Study 2. Proactive administration of thyroid
hormone replacement therapy appeared to prevent the
development of axitinib-related grade 3/4 fatigue.
In Study 2, a slight TSH decrease below the lower limit
of normal range was observed in two patients between day
120 and day 170, and between day 320 and day 340
(Fig. 3b). This observation occurred during thyroid hor-
mone replacement therapy and TSH decrease normalized
with dose reduction or a temporary interruption of thyroid
hormone replacement therapy.
In the three patients in Study 2 who received at least
three cycles of axitinib treatment, changes in TSH levels
mirrored the kinetics of change in total cholesterol levels.
Meanwhile, no clear correlation was observed between
TSH levels and CPK.
The relationship between changes in levels of TSH and
axitinib plasma AUC was also investigated. When data for
patients in both studies were analyzed, TSH change
(baseline to cycle 2 day 1) was found to increase linearly
with AUC12, with a correlation coefficient r of 0.723 (95%
confidence interval [CI] 0.361 to 1.000; P=0.0180)
(Fig. 4).
Soluble plasma biomarkers
Table 6 shows changes in plasma concentrations of VEGF,
sVEGFR-2, sVEGFR-3 and sKIT from baseline to cycle
2 day 1 inbothstudies.Significant increases inmedianVEGF
levels (+242%) and decreases in median plasma sVEGFR-2
and sVEGFR-3 levels (–38% and –53%, respectively) were
observed. An inverse relationship was seen between percent
change in sVEGFR-2 levels (baseline to cycle 2 day 1) and
axitinib AUC12 with a correlation coefficient r of –0.940
(95% CI –1.000 to –0.841; P<0.0001) (Fig. 5).
Table 2 Common treatment-related adverse events (pooled data from
Study 1 and Study 2; N=18)
Adverse event All grades, n (%) Grade 3/4, n (%)
Fatigue 15 (83) 5 (28)
Anorexia 13 (72) 0
Diarrhea 12 (67) 0
Hand–foot syndrome 12 (67) 1 (6)
Hypertension 11 (61) 6 (33)
Stomatitis 10 (56) 0
Hoarseness 9 (50) 0
Constipation 7 (39) 0
Rash 6 (33) 0
Epistaxis 5 (28) 0
Nausea 4 (22) 0
Headache 4 (22) 0
Table 3 Common treatment-related laboratory abnormalities (pooled
data from Study 1 and Study 2; N=18)
Adverse event All grades, n (%) Grade 3/4, n (%)
Non-hematologic
TSH increased 13 (72) 0
Proteinuria 9 (50) 2 (11)
Hematuria 7 (39) 0
Lipase increased 6 (33) 0
Blood glucose increased 5 (28) 0
ALP increased 4 (22) 1 (6)
AST increased 4 (22) 0
TSH decreased 4 (22) 0
Hematologic
Platelet count decreased 6 (33) 0
Neutrophil count decreased 3 (17) 1 (6)
Lymphocyte count
decreased
1 (6) 0
ALP alkaline phosphatase; AST aspartate aminotransferase; TSH
thyroid-stimulating hormone
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The majority of patients (n=16; 89%) had disease progres-
sion before enrollment. Following treatment with axitinib, a
reduction in tumor size was observed in 11 of 17 (65%)
evaluable patients who had a target lesion. Tumor size
decreased by≥30% in two patients with colorectal cancer
and by≥20% in two patients (one each with NSCLC and
thymic cancer). Additionally, stable disease (≥24 weeks)
was noted in six patients (one each with colorectal cancer,
NSCLC, thymic cancer, synovial sarcoma, esophageal
malignant melanoma and pancreatic cancer).
Discussion
Preliminary population pharmacokinetic analyses of
cytokine-refractory mRCC patients indicated that patients
who achieved a higher exposure to axitinib (AUC) while
receiving 5 mg BID had higher response rate and longer
overall survival. Additionally, retrospective analyses of two
clinical trials of axitinib in mRCC demonstrated that patients
who developed at least one dBP measurement ≥90 mm Hg
during therapy had a longer overall survival, higher probabil-
ity of a partial response and greater decreases in tumor size
[15]. These findings suggested that increasing the axitinib
dose above a starting dose of 5 mg BID in a select group of
patients who tolerate the drug without experiencing hyper-
tension may result in improved efficacy. Thus, in axitinib
clinical trials, dose titration from a starting dose of 5 mg
B I Dt o7m gB I Da n dt h e nt oam a x i m u m1 0m gB I Di s
recommended if no treatment-related adverse events
grade >2 are observed and BP is ≤150/90 mm Hg for 2
consecutive weeks with axitinib 5 mg BID. However, the
pharmacokinetic profile following 5-mg, 7-mg and
10-mg single dosing of axitinib has not been evaluated
in either Western or Japanese subjects. In Study 2,
axitinib pharmacokinetics following 5-mg, 7-mg and 10-mg
single dosing was further evaluated.
Single and continuous dosing of axitinib was generally
well tolerated in the Japanese patients studied here. The
adverse event profile was similar to that seen in other studies
of axitinib in Caucasian populations [5–9, 16]. Toxicities
associated with axitinib therapy were generally manageable
in the current studies. Major grade 3/4 adverse events
included fatigue and hypertension. Fatigue (all grades)
occurred in 83% of patients in the two studies, with grade
3/4 fatigue seen in 42% of patients in Study 1. Comparable
rates of fatigue were reported by Rini et al [6] in a study of
P
l
a
s
m
a
 
C
o
n
c
e
n
t
r
a
t
i
o
n
 
(
n
g
/
m
L
)
Time (h)
0
20
40
60
80
100
120
6 0 12 18 24 30 36
5 mg
7 mg
10 mg
Fig. 2 Axitinib plasma concentration over time following single
dosing in Study 2; pharmacokinetic parameters were measured
following a single dose of axitinib (N=6)
Table 4 Pharmacokinetic parameters following single and continuous dosing of axitinib (Study 2; N=6)
Single dosing
Dose Mean
a (%CV) Mean
a (%CV) Mean
a (%CV) Median (min, max)
Cmax, ng/mL AUCInf, ng·hr/mL t1/2,h T max,h
5 mg 17.0 (70) 142 (86) 4.8 (59) 4.10 (3.95, 6.02)
7 mg 23.3 (88) 181 (80) 5.1 (51) 4.00 (0.983, 9.88)
10 mg 34.9 (115) 288 (91) 5.9 (59) 4.02 (2.05, 6.00)
Continuous dosing (cycle 1 day 15)
Dose Mean
a (%CV) Mean
a (%CV) Median (min, max) Mean
a (%CV)
Cmax, ng/mL AUC12, ng·hr/mL Tmax,h R ac
5 mg BID 21.4 (84) 138 (78) 4.04 (3.93, 7.70) 1.37 (28)
a Values are measured in geometric mean for Cmax, AUCinf, AUC12, and Rac and arithmetic mean for t1/2
%CV percent coefficient of variation; AUC12 area under the plasma concentration–time curve from time zero to 12 h; AUCInf area under the
plasma concentration–time curve from time zero to infinity; BID twice daily; Cmax maximum plasma concentration; Rac accumulation ratio; t1/2
terminal-phase plasma half-life; Tmax time to first occurrence of Cmax
1060 Invest New Drugs (2012) 30:1055–1064axitinib in sorafenib-refractory RCC. For the six patients in
Study 2, proactive thyroid hormone replacement therapy
(according to TSH levels) seemed useful to prevent the
development of grade 3/4 fatigue related to axitinib treatment.
Theseresultssuggestthataxitinib-relatedgrade3/4fatiguemay
be preventable through careful monitoring of TSH levels and
use of thyroid hormone replacement therapy as needed to
maintain a euthyroid state. It is known that anemia is frequently
associated with hypothyroidism [17, 18]. In the present two
phase I studies, anemia was not reported as an adverse event.
Elevation of hemoglobin was reported in patients treated with
VEGFR inhibitors such as axitinib, sunitinib and sorafenib
[11, 19–21]. This could obscure the development of anemia-
associated hypothyroidism, and it thus may be difficult to
investigate the relationship between anemia and hypothyroid-
ism with the treatment of VEGFR inhibitors.
Elevation of thyroglobulin was observed in all three patients
who continued treatment with axitinib for ≥3 months in Study
2.Thyroglobulinissynthesizedbythe thyroidglandtoproduce
the thyroid hormones T4 and T3. Increased serum levels of
thyroglobulin can suggest Graves’ disease or some forms of
thyroiditis such as subacute thyroiditis or destructive thyroid-
itis. The observed changes in thyroglobulin suggest that
transient subacute thyroiditis and subsequent hypothyroidism
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Fig. 3 Changes over time in Study 2 patient laboratory levels: a
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(free T4); e thyroglobulin. LLN lower limit of normal range; ULN
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Table 5 Treatment-related fatigue in Study 1 and Study 2
Study Fatigue
All grades, n (%) Grade 3/4, n (%)
Study 1 (N=12) 10 (83) 5 (42)
Study 2 (N=6)
a 5 (83) 0
aFour patients received thyroid hormone replacement therapy
Invest New Drugs (2012) 30:1055–1064 1061observed following axitinib treatment could be due to a direct
effect of this agent on the thyroid gland.
The mechanism for axitinib-induced hypothyroidism is
currently unclear; however, in vitro and in vivo studies have
demonstrated that VEGF and VEGFR mRNA and protein are
expressed in normal thyroid follicular cells, which is mediated
in part by thyroid-stimulating hormone [22–24]. These data
suggest it is possible that axitinib, a VEGFR inhibitor,
decreases thyroid function by interfering with VEGF function
and/or impairing thyroid blood flow, resulting in hypothy-
roidism. It has been postulated that hypothyroidism associated
with sorafenib may be caused by altered thyroid hormone
metabolism, increasing type 3 deiodination [25]. Hypothy-
roidism and thyroid dysfunction are commonly observed with
sunitinib (36–85% of patients) and sorafenib (~20%) [13, 26–
29]. A study of 16 patients with mRCC treated with sunitinib,
sorafenib or axitinib for ≥12 months found that thyroid
dysfunction was a common toxicity, occurring in ~40% of
patients [30]. Development of severe hypothyroidism associ-
ated with use of these agents in mRCC is infrequent, however,
and typically can be corrected by use of thyroid hormone
replacement therapy. Regular monitoring of thyroid-function
abnormalities and use of thyroid hormone replacement
therapy in patients receiving axitinib and related tyrosine
kinase inhibitors is therefore indicated.
In Study 2, it was possible to maintain a euthyroid state in
hypothyroidpatientswithcarefulmonitoringofTSHandthyroid
hormonedoseadjustments.ThedecreasesinsensitiveTSHbelow
the lower limit of normal range during thyroid hormone
replacement therapy were not associated with any symptoms of
hyperthyroidismandweresuccessfullymanagedwithtemporary
interruption ordose reduction of thyroid hormone.
The time-course of change in TSH levels and that of total
cholesterol appeared to be correlated in some patients. This
finding suggests that the observed changes in total cholesterol
values were due to axitinib-related hypothyroidism.
A correlation between occurrence of hypothyroidism and
progression-free survival was seen in some studies of sunitinib
in mRCC [31, 32]. Tyrosine kinase inhibitor–induced thyroid
dysfunction, therefore, has been proposed as a possible
surrogate marker of efficacy with antiangiogenic tyrosine
kinase inhibitors, rather than being viewed as an unwanted
toxicity [31, 33]. In the current phase I studies, increased
TSH levels were highly correlated with exposure to
axitinib (r=0.72). Additionally, a significant correlation
was noted between change in sVEGFR-2 level and
exposure to axitinib (r=–0.94). Other clinical trials of
axitinib have also observed preferential decreases in
sVEGFR levels in patients with thyroid cancer [8]o rp o o r -
prognosis acute myeloid leukemia/myelodysplastic syn-
drome [16]. These data suggest that both sVEGFR-2 and
TSH levels may serve as biomarkers of axitinib exposure.
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Fig. 5 Relationship between percentage change in soluble VEGFR-2
level from baseline to cycle 2 day 1 and AUC12 in Studies 1 and 2
(pooled data): n=13—five patients were excluded (two discontinued
treatment before cycle 2 day 1; two had axitinib dose titrated before
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Fig. 4 Relationship between change in thyroid-stimulating hormone
(TSH) levels from baseline to cycle 2 day 1 (absolute log ratio) and
AUC12 in Studies 1 and 2 (pooled data): n=10—eight patients were
excluded (two with abnormal baseline TSH; three received thyroid
hormone replacement therapy or had axitinib dose titrated before cycle
2 day 1; two discontinued treatment before cycle 2 day 1; and one did
not receive cycle 1 day 14AM dose). AUC12 area under the plasma
concentration–time curve from time zero to 12 h; CI confidence interval
Table 6 Change in plasma concentration of biomarkers from baseline
to cycle 2 day 1 (pooled data from Study 1 and Study 2; N=16
a)
Biomarker % Change in concentration from baseline
to cycle 2 day 1, median (range)
VEGF +242 (15 to 1446)
sVEGFR-2 –38 (–58 to –10)
sVEGFR-3 –53 (–94 to –16)
sKIT –2.9 (–24 to 34)
aTwo patients who discontinued treatment before cycle 2 day 1 were
excluded
sKIT soluble stem cell factor receptor; VEGF vascular endothelial
growth factor; sVEGFR-2/3 soluble VEGF receptor-2/3
1062 Invest New Drugs (2012) 30:1055–1064Inthisreport,weusedpooleddatafromtwophase Istudies
to evaluate safety, antitumor activity and biomarkers, and thus
could have potential biases for these results. However,
eligibility criteria in these two phase I studies were similar,
and the interval for patient visit, laboratory test and tumor
assessment was the same between the two protocols. The
same sample collection point for pharmacokinetics and
biomarkers was used to explore the correlation between
TSH or sVEGFR-2 level and axitinib exposure. In addition, a
standardized case report form was used for data collection in
bothstudies,whichmayreducemeasurementand/orreporting
biases. Therefore, biases introduced by using pooled data to
evaluate these data could not be substantial.
In conclusion, these results demonstrate that single and
continuous dosing of axitinib were generally well
tolerated in Japanese cancer patients. While axitinib
caused thyroid dysfunction (hypo- and hyperthyroidism),
grade 3/4 fatigue and hypothyroidism appear to be
controllable by the use of thyroid hormone replacement
therapy. Since changes in sVEGFR2 and TSH levels
correlated with axitinib plasma levels, both sVEGFR2
and TSH may potentially act as biomarkers of axitinib
exposure. Axitinib showed antitumor activity across
multiple tumor types in Japanese patients with solid tumors.
Furtherclinicalinvestigationisnecessarytoclarifytheclinical
usefulness of these potential biomarkers.
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